Comparison of Long-Term Outcomes in Real-World Patients Between Resolute Zotarilumus-Eluting and Paclitaxel-Eluting Stents in Small Vessel.
OBJECTIVE
To compare the long-term clinical outcomes between Resolute zotarolimus-eluting stent (R-ZES) and paclitaxel-eluting stent (PES) in patients with small coronary artery disease.


BACKGROUND
Patients with a small vessel diameter are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation.


METHODS
A cohort of 265 patients treated with R-ZES (185 patients with 211 lesions) or PES (80 patients with 100 lesions) in small vessel (≤2.5 mm) lesions were retrospectively analyzed. The primary end point of the study was the composite of major adverse cardiac events. The secondary end points included target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis at 3 years.


RESULTS
The baseline characteristics were similar between the 2 groups. In the R-ZES group, the mean stent diameter was smaller and the total stent length per lesion was longer. Major adverse cardiac events occurred in 8 (10%) patients who had received PES and in 7 (3.8%) patients who had received R-ZES (P = .07). The rates of 3-year TLR (2.2% vs 2.5%; P = 1.00) and TVR (5.4% vs 10.0%; P = .17) showed no statistically significant difference between the R-ZES and PES groups. The rate of stent thrombosis was 0.5% in the R-ZES group and 2.5% in the PES group (P = .21).


CONCLUSIONS
The rates of major adverse cardiac events and cardiac death were similar in the R-ZES-treated group compared with the PES-treated group.
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey kadriye11@yahoo.com.
Kadriye Orta
KO
Kilickesmez
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
Betül
B
Kocaş
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
Ahmet
A
Yildiz
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
Ugur
U
Coskun
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
Murat
M
Ersanli
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
Alev
A
Arat
Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
Tevfik
T
Gürmen
D000328:Adult; D000368:Aged; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy*; D023903:Coronary Restenosis / Q000150:complications / Q000628:therapy*; D003328:Coronary Thrombosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D002317:Cardiovascular Agents; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus
3 years; drug-eluting stent; paclitaxel-eluting stent; small vessel; zotarolimus-eluting stent